AUTHOR=Wegener Jamila , Dennhardt Sophie , Loeffler Ivonne , Coldewey Sina M. 

TITLE=Transition from acute kidney injury to chronic kidney disease in a long-term murine model of Shiga toxin-induced hemolytic-uremic syndrome

JOURNAL=Frontiers in Immunology

VOLUME=Volume 15 - 2024

YEAR=2024

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1469353

DOI=10.3389/fimmu.2024.1469353

ISSN=1664-3224

ABSTRACT=Up to 40 % of patients with typical hemolytic-uremic syndrome (HUS) characterized by microangiopathic hemolytic anemia and acute kidney injury (AKI), develop long-term consequences, most prominently chronic kidney disease (CKD). The transition from AKI to CKD, particular in the context of HUS, is not yet fully understood. The objective of this study was to establish and characterize a Shiga toxin (Stx)-induced long-term HUS model to facilitate the study of mechanisms underlying the AKI-to-CKD transition. C57BL/6 mice were subjected to 5, 10, 15 or 20 ng/kg Stx on day 0, 3 and 6 of the experiment and were sacrificed on day 14 or day 21 to identify the critical time of turn over from acute to chronic state of HUS disease. Acute disease, indicated by weight loss, plasma neutrophil gelatinase-associated lipocalin (NGAL) and urea, and renal neutrophils, diminished after 14 and returned to sham level after 21 days. HUS-associated hemolytic anemia transitioned to non-hemolytic microcytic anemia along with unchanged erythropoietin levels after 21 days. Renal cytokine levels indicated a shift towards pro-fibrotic signaling and interstitial fibrosis developed concentration-dependently after 21 days. While Stx induced the intrarenal invasion of proinflammatory M1 and pro-fibrotic M2 macrophages after 14 days, pro-fibrotic M2 macrophages were the dominant phenotype after 21 days. In conclusion, we established and characterized the first Stxinduced long-term model of HUS. This tool facilitates the study of underlying mechanisms in the early AKI-to-CKD transition following HUS and allows the testing of compounds that may protect patients with AKI from developing subsequent CKD.